Skip to main content
. 2022 Aug 10;13:909948. doi: 10.3389/fphar.2022.909948

FIGURE 4.

FIGURE 4

Consumption trend using the CDD of oral anticancer for breast cancer, chronic myeloid leukemia, and non-small-cell lung cancer